In this population of locally advanced and inoperable HCC patients, average survival rates were NOT statistically different between SRX and Sorafenib. Statistically speaking, the 8.0 vs 9.9 averages can be attributed to chance, suggesting that SRX is as good a treatment as Sorafenib in terms of survival rates. What did favour the use of SRX were that (1) it was better tolerated (i.e., fewer/less-severe side effects) and (2) it was associated with a better quality of life. These are positive news for SRX. If I were one of those patients, I would chose SRX over Sorafenib.
Sirt result, page-16
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 1 | 1 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |
Day chart unavailable